TY - JOUR
T1 - Prevalence of internalisation-associated gene, prtF1, among persisting group-A streptococcus strains isolated from asymptomatic carriers
AU - Neeman, Revital
AU - Keller, Nattan
AU - Barzilai, Asher
AU - Korenman, Zinaida
AU - Sela, Shlomo
N1 - Funding Information:
We thank Gene H Stollerman and Itzhak Ofek for discussing the paper, and Herve Bercovier for his critical reading. The study was supported by a grant from the Israeli Ministry of Health and the Wassermann Foundation award to Shlomo Sela.
PY - 1998/12/26
Y1 - 1998/12/26
N2 - Background. The failure of antibiotic treatment to eradicate group-A streptococci in up to 30% of patients with pharyngotonsillitis is unexplained. Some strains of group-A streptococci can enter respiratory epithelial cells, where they would be inaccessible to antibiotics unable to penetrate the cell membrane, such as penicillins. The fibronectin-binding proteins, F1 and SfbI, are needed for this process. We hypothesised, therefore, that an intracellular reservoir of group-A streptococci could account, at least partly, for failure to eradicate throat carriage, and that the presence of the gene for fibronectin-binding protein (F1) might be linked to the ability of a strain to persist in the throat after therapy. Methods. We investigated the frequency of prtF1-containing strains among 67 patients with pharyngotonsillitis. All patients were clinically cured, although 13 of them continued to carry group-A streptococci in the throat during or after therapy. To distinguish between persisting and recolonising strains, isolates from the 13 patients were serologically tested and compared by polymorphic DNA-amplification technique. Findings. 12 (92%) of the 13 patients with symptomless had prtF1-containing strains in the throat, with 16 (30%) of the 54 patients with eradication (p = 0.0001). Three of the 13 eradication-failure patients were recolonised with strains that differed from the pretreatment strains. Nine of the ten (90%) persisting strains carried prtF1 (p = 0.0009). Interpretation. Our findings suggest that protein-F1-mediated entry to cells is involved in the causative process of the carriage state.
AB - Background. The failure of antibiotic treatment to eradicate group-A streptococci in up to 30% of patients with pharyngotonsillitis is unexplained. Some strains of group-A streptococci can enter respiratory epithelial cells, where they would be inaccessible to antibiotics unable to penetrate the cell membrane, such as penicillins. The fibronectin-binding proteins, F1 and SfbI, are needed for this process. We hypothesised, therefore, that an intracellular reservoir of group-A streptococci could account, at least partly, for failure to eradicate throat carriage, and that the presence of the gene for fibronectin-binding protein (F1) might be linked to the ability of a strain to persist in the throat after therapy. Methods. We investigated the frequency of prtF1-containing strains among 67 patients with pharyngotonsillitis. All patients were clinically cured, although 13 of them continued to carry group-A streptococci in the throat during or after therapy. To distinguish between persisting and recolonising strains, isolates from the 13 patients were serologically tested and compared by polymorphic DNA-amplification technique. Findings. 12 (92%) of the 13 patients with symptomless had prtF1-containing strains in the throat, with 16 (30%) of the 54 patients with eradication (p = 0.0001). Three of the 13 eradication-failure patients were recolonised with strains that differed from the pretreatment strains. Nine of the ten (90%) persisting strains carried prtF1 (p = 0.0009). Interpretation. Our findings suggest that protein-F1-mediated entry to cells is involved in the causative process of the carriage state.
UR - http://www.scopus.com/inward/record.url?scp=0242592788&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(97)12452-7
DO - 10.1016/S0140-6736(97)12452-7
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 9872247
AN - SCOPUS:0242592788
SN - 0140-6736
VL - 352
SP - 1974
EP - 1977
JO - The Lancet
JF - The Lancet
IS - 9145
ER -